Jamie Kang

[Molecular Cancer] The authors investigated the mechanisms underlying the interaction and influence between microvascular invasion, which contributes to metastasis and poor prognosis of PDAC, and the tumor microenvironment.

[Journal for Immunotherapy of Cancer] Researchers demonstrated that relaxin can enhance intratumoral accumulation of programmed death-ligand 1-targeted RIT (lutetium-177-labeled atezolizumab) in a multifaceted manner to elicit synergistic antitumor immune response against desmoplastic and poorly immunogenic pancreatic tumors.

[Cell Death & Disease] Scientists utilized molecular cytology techniques, animal models, and human pancreatic cancer tissues to investigate the role of FoxM1 in Smad4 stabilization and its regulation of TGF-β signaling.

[Cancer & Metabolism] Investigators suggested that SRRM1 may serve as a predictive biomarker for gemcitabine (GEM) response in pancreatic cancer. Targeting SRRM1 in conjunction with ferroptosis inducers could offer a promising strategy to overcome GEM resistance.

[Tissue Barriers] Researchers performed an integrative analysis of 177 RNA-Seq datasets from TCGA and GTEx to characterize Claudin family alterations in PDAC.

[Gene] The authors summarize current knowledge on the multifaceted roles of ncRNAs across major cellular compartments of the tumor microenvironment, highlight key barriers that limit their diagnostic and therapeutic potential, and discuss emerging strategies that may accelerate the development of ncRNA-guided precision medicine in PDAC.